R C Mohs

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials
    R C Mohs
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Genes Brain Behav 4:129-33. 2005
  2. ncbi request reprint AMPA potentiator treatment of cognitive deficits in Alzheimer disease
    A S Chappell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neurology 68:1008-12. 2007
  3. doi request reprint Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study
    Richard C Mohs
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 17:752-9. 2009
  4. doi request reprint A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?
    Richard C Mohs
    Neuroscience, Medical, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN, USA
    Alzheimers Dement 4:S85-7. 2008
  5. ncbi request reprint Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, Ontario, Canada MIN 2E8
    Am J Psychiatry 164:900-9. 2007
  6. ncbi request reprint Neuropsychological test performance in healthy volunteers before and after donepezil administration
    Leigh J Beglinger
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Psychopharmacol 18:102-8. 2004
  7. ncbi request reprint Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease
    Michael Serby
    Departments of Psychiatry and Psychology, Mount Sinai School of Medicine, New York, NY, USA
    Am J Geriatr Psychiatry 11:371-4. 2003
  8. ncbi request reprint Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
  9. pmc Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years
    Gerda G Fillenbaum
    Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA
    Alzheimers Dement 4:96-109. 2008
  10. pmc Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology
    Michal Schnaider Beeri
    Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
    J Gerontol A Biol Sci Med Sci 60:471-5. 2005

Collaborators

Detail Information

Publications11

  1. ncbi request reprint The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials
    R C Mohs
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Genes Brain Behav 4:129-33. 2005
    ..Drug treatments for AD are usually developed by first showing a positive effect on the cognitive deficit, with later studies investigating drug effects on other clinical aspects of the disease...
  2. ncbi request reprint AMPA potentiator treatment of cognitive deficits in Alzheimer disease
    A S Chappell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neurology 68:1008-12. 2007
    ..To investigate the efficacy and safety of the positive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid modulator LY451395 in patients with mild to moderate Alzheimer disease (AD) (Mini-Mental State Examination scores 14 to 26)...
  3. doi request reprint Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study
    Richard C Mohs
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 17:752-9. 2009
    ..To examine the efficacy and tolerability of atomoxetine (ATX) in improving cognitive performance of patients with Alzheimer dementia...
  4. doi request reprint A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?
    Richard C Mohs
    Neuroscience, Medical, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN, USA
    Alzheimers Dement 4:S85-7. 2008
    ..Opportunities for government, academic researchers, advocacy groups, and the pharmaceutical industry to mitigate some of these risks and possibly speed the introduction of new therapies are mentioned...
  5. ncbi request reprint Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, Ontario, Canada MIN 2E8
    Am J Psychiatry 164:900-9. 2007
    ..This study compared the effects of duloxetine, 60 mg/day, versus placebo on cognition, depression, and pain in elderly patients with recurrent major depressive disorder...
  6. ncbi request reprint Neuropsychological test performance in healthy volunteers before and after donepezil administration
    Leigh J Beglinger
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Psychopharmacol 18:102-8. 2004
    ..While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers...
  7. ncbi request reprint Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease
    Michael Serby
    Departments of Psychiatry and Psychology, Mount Sinai School of Medicine, New York, NY, USA
    Am J Geriatr Psychiatry 11:371-4. 2003
    ....
  8. ncbi request reprint Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
    ....
  9. pmc Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years
    Gerda G Fillenbaum
    Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA
    Alzheimers Dement 4:96-109. 2008
    ..CERAD materials and data remain available for those wishing to use them...
  10. pmc Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology
    Michal Schnaider Beeri
    Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
    J Gerontol A Biol Sci Med Sci 60:471-5. 2005
    ..The present descriptive study compared diabetic and nondiabetic subjects on the severity of neuritic plaques and neurofibrillary tangles (NFTs) in the cerebral cortex and in the hippocampus...
  11. ncbi request reprint Familial patterns of risk in very late-onset Alzheimer disease
    Jeremy M Silverman
    Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Arch Gen Psychiatry 60:190-7. 2003
    ..Although genetic factors are implicated in AD with substantially earlier onset, the familial characteristics of high-incidence very late-onset AD (VLOAD, defined here as AD with onset age >/=85 years) remain unknown...